<- Go Home
PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Market Cap
CHF 1.5B
Volume
56.3K
Cash and Equivalents
CHF 59.0M
EBITDA
CHF 75.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 104.9M
Profit Margin
22.86%
52 Week High
CHF 53.25
52 Week Low
CHF 23.17
Dividend
N/A
Price / Book Value
4.40
Price / Earnings
105.58
Price / Tangible Book Value
4.48
Enterprise Value
CHF 1.6B
Enterprise Value / EBITDA
20.35
Operating Income
CHF 44.2M
Return on Equity
4.24%
Return on Assets
3.38
Cash and Short Term Investments
CHF 59.0M
Debt
CHF 149.2M
Equity
CHF 351.2M
Revenue
CHF 458.9M
Unlevered FCF
-CHF 86.0M
Sector
Life Sciences Tools and Services
Category
N/A